Aleksandra Marczak

Aleksandra Marczak

Auto-generated profile, based on publicly available information

Aleksandra Marczak

Student Research Group at the Department of Clinical Oncology and Chemotherapy, Medical University of Lublin

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
KGKarolina Garbacz
Karolina Garbacz
MMMaria Maciąg
Maria Maciąg
MPMałgorzata Pasztelan
Małgorzata Pasztelan
JPJarosław Pulikowski
Jarosław Pulikowski
MSMałgorzata Słaboń
Małgorzata Słaboń
JBJoanna Baran
Joanna Baran
Lichen planus (LP) is a chronic skin, mucous membrane, and nail disease. Lichen planus is a rare skin condition occurring in less than 1% of the general population, affecting both children and adults. Oral lichen planus (OLP) involvement is much more common. It is an autoimmune disease caused by T lymphocytes, with epigenetic factors playing a significant role in the development of autoimmune skin diseases. MicroRNAs (miRNAs), a group of non-coding RNAs, play a substantial role in regulating the immune response.1 The etiology of lichen planus in not fully understood. It can be triggered by antihypertensive drugs, beta-blockers, infections, viral hepatitis, psychological stress, and others. Cases of lichen planus appearing after recovering from COVID-19 have been reported, as well as a significant increase in cases after COVID-19 vaccination.2–5 Diagnosis is based on clinical presenstation and characteristic histopathological findings. The disease is often self-limiting, accompanied by persistent itching and painful erosions of the mucous membrane, affecting the patient’s quality of life and mental well-being. First-line treatments inculde topical corticosteroids and/or oral corticosteroids. There are reports of new potential treatments, such as biologic drugs (anti-IL12/13, anti-IL17) and Janus kinase inhibitors. Consequently, a dramatic change in lichen planus treatment can be expected in the near future. The majority of patients suffering from lichen planus develop metabolic syndrome which is the cause of other diseases. This article provides a comprehensive overview of current knowledge about lichen planus and its variants.

1 September 2020 in Journal of Education, Health and Sport
Verified
Journal Article
Closed access
PDF file
SNSylwiusz Niedobylski
Sylwiusz Niedobylski
KLKatarzyna Laszczak
Katarzyna Laszczak
KWKonrad Warchoł
Konrad Warchoł
AMAleksandra Marczak
Aleksandra Marczak
MDMaciej Dobosz
Maciej Dobosz
EOEwa Obel
Ewa Obel
Introduction and purpose: Total lack of testosterone or its level lower than 9-12 mmol/L (250-350 ng/dL) of serum in men is called hypogonadism. Due to the importance of testosterone in male body, hypogonadism usually causes a variety of symptoms, mostly of sexual nature – lack of libido, erectile dysfunction, infertility and associated psychological problems, it can though be the cause of more dangerous changes in the male body. The purpose of this study is to review possible systemic complications of male hypogonadism (with the emphasis on hypogonadotropic hypogonadism) apart from those sex-related.State of knowledge: The lack of testosterone and gonadotropins was proven to cause a number of negative changes in different systems and various clinical situations. It can negatively impact the condition of skeletal system. Although testosterone is widely thought to increase cardiovascular risk some studies show that the hypogonadism has a negative impact on it as well. Some studies hypothesised the role of hypogonadism in anaemia development, but generally it isn’t taken into account in investigation of this condition. Some studies show the impact of hypogonadism on higher risk of some metabolic and endocrine diseases. The most interesting conclusions were found in literature on oncological implications of testosterone and lack of it. It turns out that there is a number of studies showing the positive impact of relatively higher testosterone concentrations while androgen deprivation therapy is the main therapeutic option in advanced prostate cancer.Conclusions: Due to very unpleasant and possibly dangerous complications of hypogonadism endocrinologists should stay alert to signs of hypogonadism to be able to start testosterone replacement in the right moment.

1 September 2020 in Journal of Education, Health and Sport
Verified
Journal Article
Closed access
PDF file
SNSylwiusz Niedobylski
Sylwiusz Niedobylski
KLKatarzyna Laszczak
Katarzyna Laszczak
KWKonrad Warchoł
Konrad Warchoł
AMAleksandra Marczak
Aleksandra Marczak
MDMaciej Dobosz
Maciej Dobosz
EOEwa Obel
Ewa Obel
Introduction and purpose: Male hypogonadism is diagnosed in patients with total testosterone under 9-12nmol/L (250-350ng/dl) in serum which is associated with numerous symptoms which can severely lower the quality of patients life. Due to the cause and associated levels of gonadotropins it can be divided to hypergonadotropic and hypogonadotropic hypogonadism. Hypogonadotropic hypogonadism occurs far less often, but it’s considered to remain underdiagnosed. The purpose of this study is to review most of the inborn diseases that involve hypogonadotropic hypogonadism as one of their components. Current state of knowledge: Patients with Kallmann syndrome constitute the majority of confirmed hypogonadotropic hypogonadism cases, however due to variable epidemiological data and differing diagnosing processes the exact incidence cannot be estimated – it ranges from 1 in 85 000, to 1 in 5000 males and about 3-4 times less often in women. Other conditions that can occur with hypogonadotropic hypogonadism are Isolated Gonadotropin-Releasing Hormone deficiency, Gonadotropin disorders, Prader-Willi Syndrome, some pleiotropic syndromes like CHARGE syndrome, Patau syndrome, Pfeiffer syndrome, Hartsfield syndrome, Waardenburg syndrome, Bardet-Biedl syndrome, or other syndromes. The evaluation and treatment of some of these conditions does not involve hypogonadism or other gonadal disorders due to short lifespan, which cause the underestimations in hypogonadism morbidity. Conclusions: Regardless of lower incidence of hypogonadotropic hypogonadism compared to hypergonadotropic type, endocrinologists should stay aware of its under-diagnosis and actively search for signs of low gonadotropic hormones and gonadotropin-releasing hormone levels in hypogonadal patients.

13 December 2024 in Current Problems of Psychiatry
Verified
Journal Article
Open access
KNKatarzyna Nowak
Katarzyna Nowak
PSPiotr Stępień
Piotr Stępień
AMAleksandra Marczak
Aleksandra Marczak
IHIzabela Halczuk
Izabela Halczuk
BSBartłomiej Stachura
Bartłomiej Stachura
IHIwona Halczuk
Iwona Halczuk
Introduction: Transgender people may experience gender dysphoria, which is defined as the distress and impairment associated with a person's perception of a marked incongruity between their gender identification and their sex assigned at birth. The aim of the study is to understand the neurophysiological diversity of people with and without dysphoria, as well as to assess the genetic, endocrine and biological basis of the development of dysphoria. Material and methods: A review of the available literature was performed by searching the Google Scholar and PubMed databases using the keywords: dysphoria, gender incongruity, neurophysiology, neurophysiological diversity and dysphoria, gender dysphoria and genetics. This publication is based on a literature review covering the years 2015 - 2023. Works published before 2015 were excluded from the analysis. The SANRA scale was used to maintain the high quality of the narrative review. Results: Gender dysphoria has a polygenic basis, involving interactions between various genes and their polymorphisms. Endocrine factors are also important, so the most complete picture of the neurophysiological basis of gender dysphoria can be obtained by adding brain imaging tests and measurements of sex hormone concentrations to genetic tests. Conclusions: Determining what biological factors contribute to gender dysphoria may have a positive impact on the mental health of transgender people. Moreover, this knowledge can be used to improve the quality of diagnosis and treatment of these people. Therefore, there is a clinical need to conduct further research in this field.

17 November 2024 in Quality in Sport
Verified
Journal Article
Open access
PDF file
AMAleksandra Marczak
Aleksandra Marczak
JWJulia Krawczuk Vel Walczuk
Julia Krawczuk Vel Walczuk
MMMaria Maciąg
Maria Maciąg
MSMaciej Sobczyk
Maciej Sobczyk
KGKarolina Garbacz
Karolina Garbacz
JBJoanna Baran
Joanna Baran
Both depression and obesity are significant health, social and economic problems. Depressive disorders were the second most common psychiatric disorder in 2017 after anxiety disorders. According to data published by the World Health Organization (WHO), depression affects about 280 million people worldwide, which is about 3.8 percent of the population. The etiology of depressive disorders is very complex and still not fully understood. The theories described so far complement each other. The factors underlying the development of depressive disorders can be divided into biological, psychological and other factors. Eating disorders in the form of overweight and obesity result from a loss of balance between anabolic and catabolic processes. This is most often led by insufficient physical activity and excess caloric intake. Hormonal disorders, genetic factors and environmental factors may also play an important role in the pathogenesis of obesity. The steadily increasing number of people suffering from depression and obesity prompts the search for links between these two seemingly unrelated disease entities. According to current knowledge, these diseases are bi-directionally linked by genetic, psychological, metabolic and social factors. Depression is associated with an increase in the risk of obesity by about 37% relative to those without depression. Obesity is associated with an increase in the risk of depressive disorders by about 18%. Understanding the links that exist between depressive disorders and obesity enables the search for new therapeutic options. The most important conclusion from the scientific research conducted so far is the advantage of simultaneous treatment of obesity and depression over treating these disease entities individually.

8 September 2023 in Current Problems of Psychiatry
Verified
Journal Article
Open access
ZWZuzanna Joanna Wingralek
Zuzanna Joanna Wingralek
AMAleksandra Marczak
Aleksandra Marczak
JTJustyna Tomasik
Justyna Tomasik
AGAdrian Giermasiński
Adrian Giermasiński
MDMichał Dzikowski
Michał Dzikowski
Introduction: Borderline personality disorder (BPD) affects approximately 1%-3% of the population. As the most common personality disorder, BPD features behavioural, emotional and social dysfunctions. It often co-occurs with self-harm, suicidal tendencies and substance abuse. To date, pharmacological treatment does not provide sufficient therapeutic effects. The aim of our study is to analyse the neurobiological, genetic and environmental components in the aetiopathogenesis of BPD and to collect data on the innovative use of lithium and naltrexone in the therapy of BPD. Methods: Basing on PubMed and Google Scholar databases using the following keywords: borderline, lithium, naltrexone for papers published from 1979 to 2022. Results: Difficult childhood, and emotional, sexual and physical abuse are the strongest predictors of BPD development. The core symptoms of BPD may be related to dysfunction of the serotonin, dopaminergic, endogenous system and opioid systems. Variation in 5-HTT, COMT, FKBP5 and oxytocin receptor genes may influence the course of BPD. Imaging studies have shown structural and functional abnormalities in the prefrontal cortex, amygdala and hippocampus. Lithium reduces impulsivity, aggression, suicidal tendencies and self-harm in BPD. Naltrexone may effectively reduce self-harm without suicidal tendencies, impulsivity, substance abuse and suicidality. Conclusions: No unified model has been developed to account for environmental, genetic and neurobiological components in the pathogenesis of BPD. Understanding the mechanisms is a crucial step towards personalising treatment. The use of lithium and naltrexone may have positive therapeutic effects. Randomised clinical trials are required to establish the efficacy and safety of both drugs in long-term treatment. Keywords: borderline, lithium, naltrexone